The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Open accessAbstract
Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials. However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance. Identification of resistance mechanisms in a manner that elucidates alternative 'druggable' targets may inform effective long-term treatment strategies. Here we expressed ∼600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,002
The role of mitogen‐ and stress‐activated protein kinase pathways in melanoma
Lopez‐Bergami, P. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00908.x · Cited by 75
Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
Yamaguchi, R., Janssen, E. M., Perkins, G. A., Ellisman, M. H., Kitada, S., & Reed, J. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024102 · Cited by 79
BRAF and MEK inhibition in melanoma
Dossett, L. A., Kudchadkar, R. R., & Zager, J. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1011618 · Cited by 75
Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
Luke, J. J., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2197 · Cited by 73
Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib
Horbert, R., Pinchuk, B., Davies, P., Alessi, D. R., & Peifer, C. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00174 · Cited by 75
Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma
Wang, A., & Qi, X. (2013) · IUBMB Life · doi:10.1002/iub.1193 · Cited by 74
The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma
Huynh, C., Poliseno, L., Segura, M. F., Medicherla, R. C., Haimovic, A., Menéndez, S., Shang, S., Pavlick, A. C., Shao, Y., Darvishian, F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025264 · Cited by 71
Le, K., Blomain, E. S., Rodeck, U., & Aplin, A. E. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12092 · Cited by 72
Sweetlove, M., Wrightson, E., Kolekar, S., Rewcastle, G. W., Baguley, B. C., Shepherd, P. R., & Jamieson, S. M. F. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00135 · Cited by 71
The “ART” of Epigenetics in Melanoma: From histone “Alterations, to Resistance and Therapies”
Strub, T., Ballotti, R., & Bertolotto, C. (2020) · Theranostics · doi:10.7150/thno.36218 · Cited by 73
Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF
Thiel, A., & Ristimaki, A. P. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00281 · Cited by 78
Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Carlino, M. S., Fung, C., Shahheydari, H., Todd, J. R., Boyd, S. C., Irvine, M., Nagrial, A. M., Scolyer, R. A., Kefford, R. F., Long, G. V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0759 · Cited by 69
BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity
Cabanillas, M. E., Patel, A. P., Danysh, B. P., Dadu, R., Kopetz, S., & Falchook, G. S. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0207-9 · Cited by 69
Arnedos, M., Soria, J., André, F., & Tursz, T. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.002 · Cited by 71
A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF V600E-Mutant Brain Tumor
Wang, J., Yao, Z., Jonsson, P., Allen, A. N., Qin, A. C. R., Uddin, S., Dunkel, I. J., Petriccione, M., Manova, K., Haque, S. S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1263 · Cited by 69
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 72
Tunca, B., Tezcan, G., Çeçener, G., Egelí, Ü., Zorluoğlu, A., Yılmazlar, T., Aksoy, S. A., Yerci, Ö., Öztürk, E., Umut, G., et al. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1372-x · Cited by 69
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
Shao, Y., & Aplin, A. E. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.94 · Cited by 72
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
Hu, W., Jin, L., Jiang, C. C., Long, G. V., Scolyer, R. A., Wu, Q., Zhang, X. D., Mei, Y., & Wu, M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.441 · Cited by 72
Lehraiki, A., Cerezo, M., Rouaud, F., Abbe, P., Allegra, M., Kluza, J., Marchetti, P., Imbert, V., Chéli, Y., Bertolotto, C., et al. (2015) · Cell Discovery · doi:10.1038/celldisc.2015.30 · Cited by 67
Melanocytic tumors with MAP3K8 fusions: report of 33 cases with morphological-genetic correlations
Houlier, A., Pissaloux, D., Masse, I., Tirode, F., Karanian, M., Pincus, L. B., McCalmont, T. H., LeBoit, P. E., Bastian, B. C., Yeh, I., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0384-8 · Cited by 69
Tian, Y., & Guo, W. (2020) · Medical Science Monitor · doi:10.12659/msm.920957 · Cited by 71
Murtaza, N., Cheng, A. A., Brown, C. O., Meka, D. P., Hong, S., Uy, J. A., El-Hajjar, J., Pipko, N., Unda, B. K., Schwanke, B., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111678 · Cited by 70
Young, K., Minchom, A. R., & Larkin, J. (2012) · Future Oncology · doi:10.2217/fon.12.43 · Cited by 74
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi, A., Caramuta, S., Seashore-Ludlow, B. A., Boström, J., Robinson, J. L., Edfors, F., Tuominen, R., Kemper, K., Krijgsman, O., Peeper, D. S., et al. (2018) · Molecular Systems Biology · doi:10.15252/msb.20177858 · Cited by 66
Sclafani, F., Gullo, G., Sheahan, K. D., & Crown, J. P. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.003 · Cited by 70
Sabbatino, F., Wang, Y., Wang, X., Flaherty, K. T., Yu, L. D., Pépin, D., Scognamiglio, G., Pepe, S., Kirkwood, J. M., Cooper, Z. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1878 · Cited by 65
Self-citationERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., Moffat, J. G., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3674 · Cited by 69
Patel, S. P., Lazar, A. J., Papadopoulos, N. E., Liu, P., Infante, J. R., Glass, M. R., Vaughn, C., LoRusso, P. M., Cohen, R. B., Davies, M. A., et al. (2012) · Cancer · doi:10.1002/cncr.27790 · Cited by 66
Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance
Pastwińska, J., Karaś, K., Karwaciak, I., & Ratajewski, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188754 · Cited by 74
Civiero, L., Cirnaru, M., Beilina, A. G., Rodella, U., Russo, I., Belluzzi, E., Lobbestael, E., Reyniers, L., Hondhamuni, G., Lewis, P. A., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13369 · Cited by 67
Andreadi, C., Cheung, L.-K. M., Giblett, S. M., PATEL, B., Jin, H., Mercer, K., Kamata, T., Lee, P., Williams, A. G., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.193458.112 · Cited by 66
Basile, K. J., Abel, E. V., & Aplin, A. E. (2011) · Oncogene · doi:10.1038/onc.2011.424 · Cited by 65
The RAF-MEK-ERK Pathway: Targeting ERK to Overcome Obstacles of Effective Cancer Therapy
Yu, Z., Ye, S., Hu, G., Lv, M., Tu, Z., Zhou, K., & Li, Q. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.143 · Cited by 66
Targeting BRAF in an Inducible Murine Model of Melanoma
Hooijkaas, A. I., Gadiot, J., van der Valk, M., Mooi, W. J., & Blank, C. U. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.002 · Cited by 67
Szilágyi, A., Nussinov, R., & Csermely, P. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313010007 · Cited by 65
Developments in targeted therapy in melanoma
Amann, V. C., Ramelyte, E., Thurneysen, S., Pitocco, R., Jaberg-Bentele, N. F., Goldinger, S. M., Dummer, R., & Mangana, J. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.10.014 · Cited by 71
Self-citationBRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
Chen, B., Tardell, C., Higgins, B., Packman, K. E., Boylan, J. F., & Niu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042598 · Cited by 65
Joseph, R. W., Swaika, A., & Crozier, J. A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s31143 · Cited by 66
Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies
Lee, H. J., Wall, B., Wangari‐Talbot, J., Shin, S., Rosenberg, S. A., Chan, J. L. ‐., Namkoong, J., Goydos, J. S., & Chen, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0098 · Cited by 64
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
Larkin, J., & Fisher (2012) · Cancer Management and Research · doi:10.2147/cmar.s25284 · Cited by 63
Flaherty, K. T. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050410-105655 · Cited by 64
Self-citationFrom Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A. C., Leong, S., Diamond, J. R., & Eckhardt, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 64
Role of the apoptotic and mitotic regulator survivin in melanoma.
McKenzie, J. A., & Grossman, D. (2012) · PubMed · Cited by 63
Croucher, D. R., Iconomou, M., Hastings, J. F., Kennedy, S. P., Han, J. Z. R., Shearer, R. F., McKenna, J. A., Wan, A., Lau, J., Aparicio, S. A. J. R., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf0793 · Cited by 61
The multifaceted allosteric regulation of Aurora kinase A
Levinson, N. M. (2018) · Biochemical Journal · doi:10.1042/bcj20170771 · Cited by 65
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64
Systematic analysis of the MAPK signaling network reveals MAP3K-driven control of cell fate
Peterson, A. F., Ingram, K. S., Huang, E. J., Parksong, J., McKenney, C. D., Bever, G. S., & Regot, S. (2022) · Cell Systems · doi:10.1016/j.cels.2022.10.003 · Cited by 62
Lidsky, M. E., Antoun, G. R., Speicher, P. J., Adams, B., Turley, R. S., Augustine, C., Tyler, D. S., & Ali‐Osman, F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532432 · Cited by 62
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., Boyd, K. L., Kantrow, S. M., Splittgerber, R. C., Short, S. P., Sobolik, T., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1122 · Cited by 62
Yoshida, T., Kakegawa, J., Yamaguchi, T., Hantani, Y., Okajima, N., Sakai, T., Watanabe, Y., & Nakamura, M. (2012) · Oncotarget · doi:10.18632/oncotarget.747 · Cited by 62
Genetic progression of malignant melanoma
Tı́már, J., Vízkeleti, L., Doma, V., Barbai, T., & Rásó, E. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9613-5 · Cited by 65
Addressing the challenges of applying precision oncology
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0032-z · Cited by 65
Bockorny, B., Rusan, M., Chen, W., Liao, R. G., Li, Y. Y., Piccioni, F., Wang, J., Tan, L., Thorner, A. R., Li, T., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0464 · Cited by 61
Quan, V. L., Zhang, B., Mohan, L. S., Shi, K., Isales, M. C., Panah, E., Taxter, T., Beaubier, N. T., White, K. P., & Gerami, P. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001213 · Cited by 62
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
Joshi, M., Rice, S. J., Liu, X., Miller, B., & Belani, C. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118210 · Cited by 62
Sullivan, R. J., LoRusso, P. M., & Flaherty, K. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2151 · Cited by 63
Self-citationTargeting Oncogenic BRAF in Human Cancer
Pratilas, C. A., Xing, F., & Solit, D. B. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2011_162 · Cited by 63
Mechanisms of resistance to BCR-ABL and other kinase inhibitors
Lamontanara, A. J., Akçok, E. B. G., Kuzyk, O., & Hantschel, O. D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.009 · Cited by 65
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy
Wu, C., & Ambudkar, S. V. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.001 · Cited by 64
Desai, B. M., Villanueva, J., Nguyen, T.-T. K., Lioni, M., Xiao, M., Kong, J., Krepler, C., Vultur, A., Flaherty, K. T., Nathanson, K. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059588 · Cited by 64
Self-citationResistance patterns with tyrosine kinase inhibitors in melanoma
Dummer, R., & Flaherty, K. T. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834fca92 · Cited by 61
Self-citationThe complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells
Fey, D., Matallanas, D., Rauch, J., Rukhlenko, O. S., & Kholodenko, B. Ν. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.011 · Cited by 69
The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer
Bahrami, A., Hesari, A., Khazaei, M., Hassanian, S. M., Ferns, G. A., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25952 · Cited by 60
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells
Misek, S. A., Appleton, K. M., Dexheimer, T. S., Lisabeth, E. M., Lo, R. S., Larsen, S. D., Gallo, K. A., & Neubig, R. R. (2019) · Oncogene · doi:10.1038/s41388-019-1074-1 · Cited by 64
IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity
Freihat, L., Wheeler, J. I., Wong, A., Turek, I., Manallack, D. T., & Irving, H. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-51913-3 · Cited by 61
SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor
Kaplan, F. M., Kugel, C. H., Dadpey, N., Shao, Y., Abel, E. V., & Aplin, A. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.390906 · Cited by 60
RAS/RAF/MEK Inhibitors in Oncology
Broggini, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799320510 · Cited by 60
Li, R., Liao, G., Nirujogi, R. S., Pinto, S. M., Shaw, P. G., Huang, T., Wan, J., Qian, J. X., Gowda, H., Wu, X., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005346 · Cited by 61
The role of gene fusions in melanocytic neoplasms
Quan, V. L., Panah, E., Zhang, B., Shi, K., Mohan, L. S., & Gerami, P. (2019) · Journal of Cutaneous Pathology · doi:10.1111/cup.13521 · Cited by 59
Glutamatergic signaling in cellular transformation
Teh, J. L. F., & Chen, S. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00983.x · Cited by 59
Beauchamp, E. M., Woods, B. A., Dulak, A. M., Tan, L., Xu, C., Gray, N. S., Bass, A. J., Wong, K., Meyerson, M. M., & Hammerman, P. S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0817 · Cited by 60
Bid, H. K., Kibler, A., Phelps, D. A., Manap, S., Xiao, L., Lin, J., Capper, D., Oswald, D. J., Geier, B., DeWire, M. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0842 · Cited by 61
AMPK promotes tolerance to Ras pathway inhibition by activating autophagy
Sanduja, S., Feng, Y., Mathis, R. A., Sokol, E. S., Reinhardt, F., Halaban, R., & Gupta, P. B. (2016) · Oncogene · doi:10.1038/onc.2016.70 · Cited by 59
Sale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58
Gough, A., Chen, N., Shun, T. Y., Lezon, T. R., Boltz, R. C., Reese, C. E., Wagner, J., Vernetti, L. A., Grandis, J. R., Lee, A. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102678 · Cited by 61
The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
Thakur, M. D., & Stuart, D. D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1633 · Cited by 59
Vanneste, M., Feddersen, C. R., Varzavand, A., Zhu, E. Y., Foley, T. M., Zhao, L. Q., Holt, K. H., Milhem, M. M., Piper, R. C., Stipp, C. S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00442 · Cited by 58
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors
Cohen, N. A., Zeng, S., Seifert, A. M., Kim, T. S., Sorenson, E. C., Greer, J. B., Beckman, M. J., Santamaria‐Barria, J. A., Crawley, M. H., Green, B. L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2564 · Cited by 59
Therapy for metastatic melanoma: an overview and update
Boyle, G. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.25 · Cited by 58
p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
Krayem, M., Journé, F., Wiedig, M., Morandini, R., Najem, A., Salès, F., van Kempen, L. C. L. T., Sibille, C., Awada, A. H., Marine, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.002 · Cited by 61
Genome-wide screen of gamma-secretase–mediated intramembrane cleavage of receptor tyrosine kinases
Merilahti, J. A. M., Ojala, V. K., Knittle, A. M., Pulliainen, A. T., & Elenius, K. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-04-0261 · Cited by 58
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
Saei, A., Palafox, M., Benoukraf, T., Kumari, N., Jaynes, P. W., Iyengar, P. V., Muñoz‐Couselo, E., Nuciforo, P. G., Cortés, J., Nötzel, C., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171960 · Cited by 58
Systemic Therapies for Advanced Melanoma
Bomar, L., Senthilnathan, A., & Ahn, C. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2019.05.001 · Cited by 59
New drug targets in metastatic melanoma
Homet, B., & Ribas, A. (2013) · The Journal of Pathology · doi:10.1002/path.4259 · Cited by 58
Poell, J. B., van Haastert, R. J., de Gunst, T., Schultz, I. J., Gommans, W. M., Verheul, M., Cerisoli, F., van Noort, P. I., Prevost, G. P., Schaapveld, R. Q. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043569 · Cited by 57
Gruosso, T., Garnier, C., Abélanet, S., Kieffer, Y., Lemesre, V., Bellanger, D., Bièche, I., Marangoni, E., Sastre‐Garau, X., Mieulet, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms9583 · Cited by 70
Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R–MEK5–Erk5 Pathway
Benito-Jardón, L., Díaz‐Martínez, M., Arellano‐Sánchez, N., Vaquero-Morales, P., Esparı́s-Ogando, A., & Teixidó, J. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2762 · Cited by 63
Update on the Targeted Therapy of Melanoma
Johnson, D. B., & Sosman, J. A. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0226-8 · Cited by 56
Mangana, J., Levesque, M. P., Karpova, M. B., & Dummer, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.665872 · Cited by 56
Self-citationKeller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 55
Determinants of resistance and response to melanoma therapy
Robertson, B. M., Fane, M. E., Weeraratna, A. T., & Rebecca, V. W. (2024) · Nature Cancer · doi:10.1038/s43018-024-00794-1 · Cited by 68
Impact of Genomics on Personalized Cancer Medicine
Arteaga, C. L., & Baselga, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2019 · Cited by 57
Waanders, E., Scheijen, B., Jongmans, M. C. J., Venselaar, H., van Reijmersdal, S. V., van Dijk, A. H. A., Pastorczak, A. K., Weren, R. D. A., van der Schoot, C. E., van de Vorst, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.277 · Cited by 61
Li, C., Nguyen, V., Clark, K. N., Zahed, T., Sharkas, S., Filipp, F. V., & Boiko, A. D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813802116 · Cited by 55
Inhibition of natriuretic peptide receptor 1 reduces itch in mice
Solinski, H. J., Dranchak, P. K., Oliphant, E. N., Gu, X., Earnest, T., Braisted, J. C., Inglese, J., & Hoon, M. A. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5464 · Cited by 53
Zeiser, R., Andrlová, H., & Meiß, F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_7 · Cited by 60
Heakal, Y., KESTER, M. A., & Savage, S. W. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q363 · Cited by 55
Biology of brain metastases and novel targeted therapies: Time to translate the research
Fokas, E., Steinbach, J., & Rödel, C. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.005 · Cited by 56
Small molecule inhibitors of BRAF in clinical trials
Zambon, A., Niculescu‐Duvaz, I., Niculescu‐Duvaz, D., Marais, R., & Springer, C. J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.060 · Cited by 55
Metadata
- Authors
- Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal, M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Genomics Institute of the Novartis Research Foundation (US)
- Dana-Farber Cancer Institute (US)
- University of Zurich (CH)
- Corresponding author
- Garraway, Levi A.
- ORCID
- Johannessen, Cory M.
- Boehm, Jesse S.
- Kim, So Young
- Stransky, Nicolas
- Cogdill, Alexandria P.
- Barretina, Jordi
- Hill, David E.
- Vidal, Marc
- Zhao, Jean J.
- Yang, Xiaoping
- Alkan, Ozan
- Wilson, Christopher J.
- Myer, Vic E.
- Root, David E.
- Roberts, Thomas M.
- Golub, Todd
- Flaherty, Keith T.
- Dummer, Reinhard
- Weber, Barbara L.
- Sellers, William R.
- Wargo, Jennifer A.
- Hahn, William C.
- Garraway, Levi A.
- Venue
- Nature
- Published
- 2010-11-24
- Volume
- 468
- Issue
- 7326
- Pages
- 968-972
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3058384
- OpenAlex
- W2141674733
- Cited by
- 1,460
- References
- 30
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 32 · 2023: 55 · 2022: 45 · 2021: 56 · 2020: 67 · 2019: 91 · 2018: 78 · 2017: 102 · 2016: 107 · 2015: 121 · 2014: 158 · 2013: 186 · 2012: 177
- FWCI
- 65.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Cancer Institute (RC2CA148268, R01CA134502, K08CA115927, CA134502, R33CA128625, P50CA093683)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MAP3K8, BRAF inhibitor resistance, vemurafenib, melanoma, BRAF V600E mutation, MAPK signaling
- MeSH terms
- Vemurafenib, Allosteric Regulation, Clinical Trials as Topic, Enzyme Activation, Humans, Indoles, Melanoma, Proto-Oncogene Proteins, Sulfonamides, Gene Library, Gene Expression Regulation, Neoplastic, Open Reading Frames, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-raf, Gene Expression Profiling, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
